Is immunohistochemistry always required to diagnose lung cancer?

Advances in Anatomic Pathology

Volumn 20, Issue 5, 2013, Pages 327-333

  Rossi, Giulio ^a   Tiseo, Marcello ^b   Cavazza, Alberto ^a   Colby, Thomas V ^c  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c MAYO CLINIC   (United States)

Author keywords

diagnosis; imaging; immunohistochemistry; Lung cancer; metastasis

Indexed keywords

APOLIPOPROTEIN A; CHROMOGRANIN; CYTOKERATIN 20; CYTOKERATIN 7; EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; PROTEIN P40; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2;

AGED; ARTICLE; BRONCHUS BIOPSY; CANCER DIAGNOSIS; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MORPHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSBRONCHIAL BIOPSY; TUMOR VOLUME;

ADENOCARCINOMA; AGED; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SMOKING; SMOKING CESSATION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; UNNECESSARY PROCEDURES;

EID: 84883414342     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3182a28a24     Document Type: Article

References (47)

1. Tiseo M, Bartolotti M, Gelsomino F, et al. First-line treatment in advanced non-small cell lung cancer: The merging role of the histologic type. Expert Rev Anticancer Ther. 2009;9:425-435.
2. Schnabel PA, Smit E, de Castro Carpen? o J, et al. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME). Lung Cancer. 2012;78:263-269.
3. Thunnissen E, Kerr K, Herth FJ, et al. Challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a Working Group. Lung Cancer. 2012;76:1-18.
4. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: Diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17:206-218.
5. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer. J Clin Oncol. 2008;26: 3543-3551.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
7. Pelosi G, Rossi G, Bianchi F, et al. Immunohistochemistry by mean of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011;6:1039-1049.
8. Mukhopadhyay S, Katzenstein ALA. Subclassification of nonsmall cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.
9. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011; 24:1348-1359.
10. Pelosi G, Fabbri A, Bianchi F, et al. DNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: A novel twohit, sparing-material approach. J Thorac Oncol. 2012;7: 281-290.
11. Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25:405-415.
12. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: Strategic management of tissue for molecular testing. Semin Respir Crit Care Med. 2011;32:22-31.
13. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011;19: 313-317.
14. Khayyata S, Yun S, Pasha T, et al. Value of p63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009;37:178-183.
15. Wu M, Wang B, Gil J, et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003;119:696-702.
16. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007;15: 415-420.
17. Camilo R, Capelozzi VL, Coelho Siqueira SA, et al. Expression of p63, keratin 5/6, keratin 7 and surfactant-A in nonsmall cell lung carcinomas. Hum Pathol. 2007;37:542-546.
18. Downey P, Cummins R, Moran M, et al. If it?s not CK5/6 positive, TTF-1 negative it?s not a squamous cell carcinoma of lung. APMIS. 2008;116:526-529.
19. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin- 3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol. 2011;6: 1190-1199.
20. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5:442-447.
21. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol. 2010;5:436-441.
22. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: A retrospective study of 103 cases with surgical correlation. Cancer. 2011;117:3416-3423.
23. Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small cell lung cancer biopsies. Histopathology. 2012;61:1017-1025.
24. Ocque R, Tochigi N, Ohori P, et al. Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol. 2011;136:81-87.
25. Whithaus K, Fukuoka J, Prihoda TJ, et al. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch Pathol Lab Med. 2012;136:155-162.
26. Noh S, Shim H. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Lung Cancer. 2012;76:51-55.
27. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
28. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology. Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med. 2013;137:668-684.
29. Ordonez NG. Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: An immunohistochemical study with review of the literature. Appl Immunohistochem Mol Morphol. 2012;20:525-530.
30. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010;18:142-149.
31. Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:1759-1763.
32. Zhang PJ, Gao HG, Pasha TL, et al. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol. 2009;28:10-18.
33. Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol. 2010;34:1881-1885.
34. Turner BM, Cagle PT, Sainz IM, et al. A new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: Evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136: 163-171.
35. Bishop JA, Sharma R, Illei PB, et al. and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-22.
36. Pereira TC, Share SM, Magalha? es AV, et al. Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases. Appl Immunohistochem Mol Morphol. 2011;19:10-14.
37. Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: Histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005;29:660-665.
38. Rossi G, Cavazza A. CDX2 expression and lung cancer. Appl Immunohistochem Mol Morphol. 2006;14:249-250.
39. Toh CK, Ahmad B, Soong R, et al. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. J Thorac Oncol. 2010;5:17-22.
40. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: Its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol. 2004;28:1169-1176.
41. Quinn AM, Blackhall F, Wilson G, et al. Extrapulmonary small cell carcinoma: A clinicopathological study with identification of potential diagnostic mimics. Histopathology. 2012; 61:454-464.
42. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
43. Masai K, Tsuta K, Kawago M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2013;21:292-297.
44. Ordonez NG. A word of caution regarding napsin A expression in squamous cell carcinomas of the lung. Am J Surg Pathol. 2012;36:396-401.
45. Pelosi G, Rodriguez J, Viale G, et al. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: A major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005; 29:179-187.
46. Wu SG, Hu FC, Chang YL, et al. Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. Eur Respir J. 2013;41:417-424.
47. Quinn D, Gianlupi A, Broste S. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest. 1996;110:1474-1479.